Description: Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Home Page: abpro.com
ABPWW Technical Analysis
68 Cummings Park Drive
Woburn,
MA
01801
United States
Phone:
617 225 0808
Officers
| Name | Title |
|---|---|
| Mr. Eugene Y. Chan M.D. | Co-Founder, Chairman & Secretary |
| Mr. Ian Chan | Co-Founder, President, CEO, Secretary & Director |
| Mr. Richard J. Mitrano | Senior Vice President of Finance |
| Mr. Christian Zapf | Senior Vice President of Corporate Development & General Counsel |
| Robert J. Markelewicz Jr., M.D. | Chief Medical Officer & Treasurer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-03-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |